期刊文献+

他汀类药物治疗非缺血性心脏病慢性心衰的临床研究 被引量:8

Clinical research of the effect of statin on non-ischemic heart failure
下载PDF
导出
摘要 目的:探讨他汀类药物治疗非缺血性心脏病慢性心衰的疗效。方法:连续入选60例慢性非缺血性心脏病心衰患者,常规标准治疗稳定1月后随机分为阿托伐他汀20mg组(n=28例),安慰剂组(n=32例)。测量基线水平的NYHA分级、血浆脑利钠肽(BNP)、超声心动图的左室射血分数(LVEF)、左室舒张末期内径(LVEDD)以及6分钟步行距离。分别于治疗12周和24周后重复测量上述相关参数。观察其疗效。结果:治疗12周后阿托伐他汀20mg组NYHA分级、BNP以及6min步行距离均显著改善,且优于对照组(P均<0.05);治疗24周后阿托伐他汀20mg组LVEDD、LVEF显著改善,且优于对照组(P均<0.05)。结论:他汀类短期治疗能改善慢性非缺血性心脏病心衰患者的心功能、BNP及6分钟步行距离;中长期治疗有望提高LVEF、缩小LVEDD,所以他汀类有益于慢性心脏病心衰的治疗。 Objective: To investigate the efficacy of statin on non-ischemic heart failure patients. Methods: A total of 60 non ischemic heart failure patients after standard therapy for 1 month were randomly divided into atorvastatin group (n=28) and control group (n= 32). The changes on the degree of New York heart association (NYHA), brain natriurenc Peptide (BNP). left venrricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and six-minutes walk distance (6MWD) were observed after 12 weeks and 24 weeks. Results: In atorvastatin group, NYHA stage, BNP and 6MWD significantly improved (P〈0.05 all), and more than those of control group (P〈0.05) after 12 weeks treatments. LVEDD significantly reduced and LVEF significantly increased (P〈 0.05 all) and improved more than those of control group (P〈0.05) after 24 weeks treatments. Conclusion: Statin can improve heart function. BNP and 6MWD in chronic non-ischemic heart failure patients after short-term treatments and may increase LVEF and reduce LVEDD after mid-term or long-term treatments. Statin is helpful for chronic heart failure patients.
出处 《心血管康复医学杂志》 CAS 2008年第4期341-344,共4页 Chinese Journal of Cardiovascular Rehabilitation Medicine
基金 上海交通大学附属胸科医院科研基金资助项目(YZ06-16)
关键词 心力衰竭 缺血性 阿托伐他汀 利钠肽 心室功能 Heart failure, congestive Atorvastatin Natriuretic peptide, brain Ventricular function, left
  • 相关文献

参考文献13

  • 1Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin Ⅱ- induced cardiac hypertrophy in cultured neonatal rat heart cells [J]. EurJPharmacol, 1997, 376: 139-148.
  • 2Chen MS, Xu FP, Wang YZ, et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis[J]. J Mol Cell Cardiol, 2004, 37:889-896.
  • 3Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin Ⅱ -induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor [J]. Circulation, 2001, 104, 576-581.
  • 4Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cadiomyophy [J]. Circulation, 2001, 104: 317-324.
  • 5Hernandez PC, Perez SD, Navarro AJ, et al. Effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells[J]. J Clin Invest, 1998, 101: 2711-2719.
  • 6Wassmann S, Laufs U, Baumer AT, et al. HMG--CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygenspecies [J] Hypertension, 2001, 37: 1450-1457.
  • 7Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells [J]. Arterioscler Thromb Vasc Biol, 2001, 21 (12): 1896-1901.
  • 8Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients [J]. Atherosclerosis, 2004, 177 (1):161-166.
  • 9Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure [J]. Circulation, 2003, 107: 2493-2498.
  • 10涂春莲,陈伟,周明成,王莹,许其倓.他汀类药物短期治疗慢性心衰对心功能和细胞因子影响的临床观察[J].实用诊断与治疗杂志,2005,19(8):572-573. 被引量:11

二级参考文献46

  • 1高金库,何书静,张明.强化降脂对急性冠脉综合征PCI患者远期疗效的影响[J].心血管康复医学杂志,2005,14(3):219-219. 被引量:4
  • 2Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J]. N Engl J Med, 1996,335 (14) : 1001.
  • 3The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients With coronary heart disease and a broad range of initial cholesterol levels [J]. N Engl J Med, 1998,339 (19): 1349-1357.
  • 4Rosenson RS, Tangney CE, Casev LC, et al. Inhibition of proinflammatory cytokine production by pravastatin [J]. Lancet, 1999, 353 (9157):983-984.
  • 5Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease [J]. Atherosclerosis, 2001, 157 (2):463-469.
  • 6Strehlow K, Wassmann S, Bohm M, et al, Angiotensin AT1 receptor over-expression in hypercholesterolaemia [J], Ann Med, 2000, 32 (6): 386-389.
  • 7Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reduetase inhibitor, on the expression of adhesion molecules on human monoeyte cell line [J]. Int J Immunopharmacol, 1996, 18 (11):669-675.
  • 8Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction[J]. Circulation, 1995, 92 (11) : 3172-3177.
  • 9Waiter DH, Schachinger V, Eisner M, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the P1A2 allele of the platelet glycoprotein lagene [J]. Eur Heart J, 2001, 22 (7):587-595.
  • 10Hayashidani S, Tsutsui H, Shiomi T, et al. Fliavastatin, a 3-Hydroxy-3-Methylglutaryl coenzyme a reduetase inhibitor, attenuates left ventrieular remodeling and failure after experimental myocardial infarction [J]. Circulation, 2002, 105 (7): 868-873.

共引文献26

同被引文献71

引证文献8

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部